Instil Bio, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Instil Bio, Inc. (TIL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.04M, a 43.20% decline year-over-year.
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $985.00K, a 71.82% decline year-over-year.
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.77M, a 56.54% decline year-over-year.
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.82M, a 56.29% decline year-over-year.
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.69M, a 49.63% decline from fiscal 2024.
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $17.26M, a 5.00% decline from fiscal 2023.
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $18.17M, a 40.32% decline from fiscal 2022.
- Instil Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $30.44M, a 16.20% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.04M 10-Q · filed 2026-08-13 | $2.02M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $985.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $8.69M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $1.77M 10-Q · filed 2025-11-13 | $3.59M derived: sum of 2 quarters · filed 2026-08-13 | $7.09M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.82M 10-Q · filed 2026-08-13 | $5.32M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $3.50M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $17.26M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $4.07M 10-Q · filed 2025-11-13 | $8.24M derived: sum of 2 quarters · filed 2025-11-13 | $12.76M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $4.17M 10-Q · filed 2025-11-13 | $8.69M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $4.51M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $18.17M 10-K · filed 2025-03-04 | |||
| 2023-09-30 | $4.67M 10-Q · filed 2024-11-13 | $9.08M derived: sum of 2 quarters · filed 2024-11-13 | $13.61M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $4.41M 10-Q · filed 2024-11-13 | $8.94M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $4.53M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $30.44M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $7.99M 10-Q · filed 2023-11-13 | $16.30M derived: sum of 2 quarters · filed 2023-11-13 | $23.80M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $8.32M 10-Q · filed 2023-11-13 | $15.81M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $7.49M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $26.20M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $8.73M 10-Q · filed 2022-11-14 | $14.47M derived: sum of 2 quarters · filed 2022-11-14 | $17.28M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $5.75M 10-Q · filed 2022-11-14 | $8.56M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $2.81M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $1.71M 10-K · filed 2022-03-07 | |||
| 2020-09-30 | $331.00K 10-Q · filed 2021-11-15 | $1.23M derived: sum of 2 quarters · filed 2021-11-15 | $1.29M derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $899.00K 10-Q · filed 2021-11-15 | $961.00K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $62.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |